According to Zacks, “DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota. “
Shares of NASDAQ DMAC opened at $2.82 on Wednesday. The business has a 50 day simple moving average of $3.09 and a 200 day simple moving average of $3.15. DiaMedica Therapeutics has a 52 week low of $1.70 and a 52 week high of $5.93. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.97 and a quick ratio of 8.97.
Hedge funds have recently bought and sold shares of the business. Commonwealth Equity Services LLC acquired a new position in shares of DiaMedica Therapeutics during the 3rd quarter worth $27,000. BlackRock Inc. boosted its holdings in DiaMedica Therapeutics by 159.7% in the second quarter. BlackRock Inc. now owns 27,075 shares of the company’s stock worth $134,000 after purchasing an additional 16,651 shares in the last quarter. Vanguard Group Inc. bought a new stake in DiaMedica Therapeutics in the second quarter worth $170,000. Millennium Management LLC increased its position in DiaMedica Therapeutics by 54.6% during the third quarter. Millennium Management LLC now owns 70,919 shares of the company’s stock worth $145,000 after buying an additional 25,037 shares during the last quarter. Finally, Worth Venture Partners LLC increased its position in DiaMedica Therapeutics by 10.6% during the second quarter. Worth Venture Partners LLC now owns 132,514 shares of the company’s stock worth $657,000 after buying an additional 12,651 shares during the last quarter. 8.01% of the stock is owned by institutional investors.
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.
Recommended Story: How can investors invest in the S&P/TSX Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.